Evidence map›Paper›PMID 29532430›Full record

ArticleEndocrine2018

Complete evaluation of pituitary tumours in a single tertiary care institution.

Dimitrios Askitis, Damianos Tsitlakidis, Nicolle Müller, Albrecht Waschke, Gunter Wolf, Ulrich Alfons Müller, Christof Kloos

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Transnasal Transsphenoidal Approach for Pituitary Tumors: An ENT Perspective.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Dimitrios AskitisEndocrinology and Metabolic Diseases Department, Internal Medicine III, Jena University Hospital, Jena, Germany. dimitrios.askitis@gmail.com.ORCID 0000-0003-3844-8348
Damianos TsitlakidisEndocrinology and Metabolic Diseases Department, Internal Medicine III, Jena University Hospital, Jena, Germany.
Nicolle MüllerEndocrinology and Metabolic Diseases Department, Internal Medicine III, Jena University Hospital, Jena, Germany.
Albrecht WaschkeDepartment of Neurosurgery, Jena University Hospital, Jena, Germany.
Gunter WolfEndocrinology and Metabolic Diseases Department, Internal Medicine III, Jena University Hospital, Jena, Germany.
Ulrich Alfons MüllerEndocrinology and Metabolic Diseases Department, Internal Medicine III, Jena University Hospital, Jena, Germany.
Christof KloosEndocrinology and Metabolic Diseases Department, Internal Medicine III, Jena University Hospital, Jena, Germany.
Jena University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe retrospectively evaluated all patients with pituitary tumours treated in our department from 1/1/1997 to 01/11/2014. PATIENTS AND

methodsTwo hundred and fifteen patients (124 females, 91 males, mean age 50.9 years) were treated because of pituitary tumours. All patients underwent basal hormonal analysis and when required dynamic testing in order to check for hormonal activity. Pituitary masses were divided into groups concerning their hormonal status and were further classified according to gender, age at diagnosis, tumour size, and the development of postoperative pituitary insufficiency when neurosurgical intervention was conducted.

resultsOne hundred and twenty-one patients had hormonally inactive tumours (non-functional adenomas; 56.3%), 57 prolactinomas (26.5%), 17 growth hormone secreting adenomas (7.9%), 16 Cushing's disease (7.4%), and 4 craniopharyngiomas (1.9%). Tumours with maximum size <1 cm (microadenomas) were detected in 62 patients (28.8%) and ≥1 cm (macroadenomas) in 153 (71.2%) of all cases (rate 1:2.5). Ninty eight patients (45.6%) had surgery (87 transsphenoidal and 11 transcranial), of this group 34 with hormonally active tumours (37.8% of the 90 patients of this subcohort). Indications for surgery were an increased risk or manifestation of chiasma syndrome and clinical symptoms due to hormonal hypersecretion. Complete [32 cases (32.6%)] or partial [33 cases (33.7%)] postoperative insufficiency in minimum one pituitary axis was present in 65/98 (66.3%) of the operated patients.

conclusionsPituitary adenoma prevalence is rising due to widely available imaging procedures. The majority of the tumours in our cohort were macroadenomas and hormonally inactive. Tumour extirpation via the transsphenoidal or transcranial route resulted in functional pituitary impairment of variable extent in 2/3 of the patients.

Indexed as

AdenomaAdolescentAdultAgedAged, 80 and overFemaleGermanyHumansMaleMiddle AgedPituitary GlandPituitary NeoplasmsRetrospective StudiesYoung AdultEpidemiologyPituitary tumoursThuringia

Identifiers

PMID29532430
OpenAlexW2790767497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.